<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        290-325-18
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2018
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        VENAXINE XR 75 MG CAPSULES
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        VENLAFAXINE HYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        75
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Modified-release capsule
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        14
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        33.85
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AX16 
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Venaxine XR is an antidepressant that belongs to a group of medicines called serotonin and norepinephrine reuptake inhibitors (SNRIs). This group of medicines is used to treat depression and other conditions such as anxiety disorders.<br />It is thought that people who are depressed and/or anxious have lower levels of serotonin and noradrenaline in the brain. It is not fully understood how antidepressants work, but they may help by increasing the levels of serotonin and noradrenaline in the brain.<br />Venaxine XR is a treatment for adults with depression. It is also a treatment for adults with the following anxiety disorders: generalised anxiety disorder, social anxiety<br />disorder (fear or avoidance of social situations) and panic disorder (panic attacks). Treating depression or anxiety disorders properly is important to help you get better. If it is not treated, your condition may not go away and may become more serious and more difficult to treat.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>IMPORTANT THINGS YOU SHOULD KNOW ABOUT VENAXINE XR</strong><br />Please read all of this leaflet before you start to take your medicine as it contains important information about Venaxine XR</p><ul><li>Venaxine XR is used to treat depression, severe and persistent anxiety known as generalized anxiety disorder (GAD), social anxiety disorder (also known as social phobia) and panic disorder (panic attacks)</li><li>Venaxine XR is not for use in children and adolescents &ndash; see in section 2 &lsquo;Children and adolescents&rsquo; If you have any concerns about how you feel, or about this medication, it is important that you talk to your doctor - even if you feel anxious or worried about doing so. You may find it helpful to tell a friend or relative that you are depressed or suffering from an anxiety disorder, and that you have been prescribed this medication; it might be useful to show them this leaflet.</li><li>Venaxine XR may not start to work immediately. Some people taking antidepressants may feel worse before feeling better. Your doctor may ask to see you again a couple of weeks after you start treatment and then regularly until you start to feel well again. Tell your doctor if you do not start to feel better.</li><li>Some people who are depressed may think of harming or killing themself. If this happens you should see your doctor or go to a hospital straight away &ndash; see in section 2 &lsquo;Thoughts of suicide and worsening of your depression or anxiety disorder&rsquo;</li><li>If you take too many capsules it is important to seek immediate medical attention, even if you feel well, because of the risk of serious side effects</li><li>Do not stop taking Venaxine XR or change your dose without the advice of your doctor even if you feel better. If you stop taking Venaxine XR abruptly you may get withdrawal reactions &ndash; see in section 3 &lsquo;If you stop taking Venaxine XR&rsquo;</li><li>If you have heart problems such as fast or irregular heart rate or high blood pressure you should talk to your doctor before taking Venaxine XR &ndash; see in section 2 &lsquo;Before you take Venaxine XR&rsquo;</li><li>Taking certain other medicines with Venaxine XR may cause problems. You should tell your doctor if you are taking any other medicines &ndash; see in section 2 &lsquo;What you need to know before you take Venaxine XR&rsquo;</li><li>See your doctor without delay if you feel restless and feel like you can&rsquo;t keep still, feel &lsquo;high&rsquo; or very over-excited, have jerky muscle movements which you can&rsquo;t control. See section 4 &ndash; &lsquo;Possible side effects&rsquo;</li></ul><p><strong>If you are pregnant, or intend to become pregnant, or breast-feeding</strong>, you should talk to your doctor &ndash; see in section 2 &lsquo;Pregnancy and breast-feeding&rsquo; More information on all of these points is provided in the rest of this leaflet.<br /><strong>Read all of this leaflet carefully before you start taking this medicine </strong>because it contains important information for you.</p><table border="1" cellspacing="1" cellpadding="1" style="width:937px"><tbody><tr><td style="width:934px"><strong>Suicidality in Children and Adolescents</strong><br />Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders.<br />Anyone considering the use of Venaxine XR or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Venaxine XR is not approved for use in pediatric patients. (<strong>See WARNINGS and PRECAUTIONS</strong>, Pediatric Use.)<br />Pooled analyses of short-term (4 to 16 weeks) placebocontrolled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.</td></tr></tbody></table><p><strong>Do not take Venaxine XR</strong></p><ul><li>If you are allergic to venlafaxine or any of the other ingredients of this medicine (listed in section 6).</li><li>If you are also taking, or have taken within the last 14 days, any medicines known as irreversible monoamine oxidase inhibitors (MAOIs), used to treat depression or Parkinson&rsquo;s disease. Taking an irreversible MAOI together with Venaxine XR, can cause serious or even life-threatening side effects. Also, you must wait at least 7 days after you stop taking Venaxine XR before you take any MAOI (see also the section entitled &ldquo;Other medicines and Venaxine XR&rdquo; and the information in that section about &lsquo;Serotonin Syndrome&rsquo;).</li></ul><p><strong>Warnings and precautions</strong><br />Talk to your doctor or pharmacist before taking Venaxine XR:</p><ul><li>If you use other medicines that taken together with Venaxine XR could increase the risk of developing serotonin syndrome (see the section &ldquo;Other medicines and Venaxine XR&rdquo;).</li><li>If you have eye problems, such as certain kinds of glaucoma (increased pressure in the eye).</li><li>If you have a history of high blood pressure.</li><li>If you have a history of heart problems.</li><li>If you have been told that you have an abnormal heart rhythm.</li><li>If you have a history of fits (seizures).</li><li>If you have a history of low sodium levels in your blood (hyponatraemia).</li><li>If you have a tendency to develop bruises or a tendency to bleed easily (history of bleeding disorders), or if you are taking other medicines that may increase the risk of bleeding e.g., warfarin (used to prevent blood clots).</li><li>If you have a history of, or if someone in your family has had, mania or bipolar disorder (feeling over-excited or euphoric).</li><li>If you have a history of aggressive behaviour.</li></ul><p>Venaxine XR may cause a sensation of restlessness or an inability to sit or stand still during the first few weeks of treatment. You should tell your doctor if this happens to you.<br /><u>Thoughts of suicide and worsening of your depression or anxiety disorder</u><br />If you are depressed and/or have anxiety disorders, you can sometimes have thoughts of harming or killing yourself. These may be increased when you first start taking<br />antidepressants, since these medicines all take time to work, usually about two weeks, but sometimes longer.<br />You may be more likely to think like this:</p><ul><li>If you have previously had thoughts about killing yourself or harming yourself.</li><li>If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behaviour in young adults (less than 25 years old) with psychiatric conditions who were treated with an antidepressant.</li></ul><p>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away.<br />You may find it helpful to tell a relative or close friend that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behaviour.<br /><u>Dry mouth</u><br />Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of tooth decay (caries). Therefore, you should take special care in your<br />dental hygiene.<br /><u>Diabetes</u><br />Your blood glucose levels may be altered due to Venaxine XR. Therefore, the dosage of your diabetes medicines may need to be adjusted.<br /><strong>Children and adolescents</strong><br />Venaxine XR should normally not be used for children and adolescents under 18 years. Also, you should know that patients under 18 have an increased risk of side effects, such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines. Despite this, your doctor may prescribe this medicine for patients under 18 because he/she decides that this is in their best interests. If your doctor has prescribed this medicine for a patient under 18, and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking Venaxine XR. Also, the long-term safety effects concerning growth, maturation and cognitive and behavioural development of this medicine in this age group has not yet been demonstrated.<br /><strong>Other medicines and Venaxine XR</strong><br />Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.<br />Your doctor should decide whether you can take Venaxine XR with other medicines.<br />Do not start or stop taking any medicines, including those bought without a prescription, natural and herbal remedies,<br />before checking with your doctor or pharmacist.</p><ul><li>Monoamine oxidase inhibitors which are used to treat depression or Parkinson&rsquo;s disease <strong>must not be taken with Venaxine XR</strong>. Tell your doctor if you have taken these medicines within the last 14 days. (MAOIs: see the section &ldquo;What you need to know before you take Venaxine XR&rdquo;).</li><li><strong>Serotonin syndrome:</strong>&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; A potentially life-threatening condition or Neuroleptic Malignant Syndrome (NMS)-like reactions (see the section &ldquo;Possible Side Effects&rdquo;), may occur with venlafaxine treatment, particularly when taken with other medicines.</li></ul><p>Examples of these medicines include:</p><ul><li>Triptans (used for migraine)</li><li>Other medicines to treat depression, for instance SNRIs, SSRIs, tricyclics, or medicines containing lithium</li><li>Medicines containing linezolid, an antibiotic (used to treat infections)</li><li>Medicines containing moclobemide, a MAOI (used to treat depression)</li><li>Medicines containing sibutramine (used for weight loss)</li><li>Medicines containing tramadol, fentanyl, tapentadol, pethidine, or pentazocine (used to treat severe pain)</li><li>Medicines containing dextromethorphan (used to treat coughing)</li><li>Medicines containing methadone (used to treat opioid drug addiction or severe pain)</li><li>Medicines containing methylene blue (used to treat high levels of methaemoglobin in the blood)</li><li>Products containing St. John&rsquo;s Wort (also called Hypericum perforatum, a natural or herbal remedy used to treat mild depression)</li><li>Products containing tryptophan (used for problems such as sleep and depression)</li><li>Antipsychotics (used to treat a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, unclear reasoning and becoming withdrawn)</li></ul><p>Signs and symptoms of serotonin syndrome may include a combination of the following: restlessness, hallucinations, loss of coordination, fast heart beat, increased body temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting. In its most severe form, serotonin syndrome can resemble<br />Neuroleptic Malignant Syndrome (NMS). Signs and symptoms of NMS may include a combination of fever, fast heart beat, sweating, severe muscle stiffness, confusion,<br />increased muscle enzymes (determined by a blood test).<br /><strong>Tell your doctor immediately, or go to the casualty department at your nearest hospital if you think serotonin syndrome is happening to you.</strong><br />You must tell your doctor if you are taking medicines that can affect your heart rhythm.<br />Examples of these medicines include:</p><ul><li>Antiarrhythmics such as quinidine, amiodarone, sotalol or dofetilide (used to treat abnormal heart rhythm)</li><li>Antipsychotics such as thioridazine (See also Serotonin syndrome above)</li><li>Antibiotics such as erythromycin or moxifloxacin (used to treat bacterial infections)</li><li>Antihistamines (used to treat allergy)</li></ul><p>The following medicines may also interact with Venaxine XR and should be used with caution. It is especially important to mention to your doctor or pharmacist if you are taking medicines containing:</p><ul><li>Ketoconazole (an antifungal medicine)</li><li>Haloperidol or risperidone (to treat psychiatric conditions)</li><li>Metoprolol (a beta blocker to treat high blood pressure and heart problems)</li></ul><p><strong>Venaxine XR with food, drink and alcohol</strong><br />Venaxine XR should be taken with food (see section 3 &ldquo;How to take Venaxine XR&rdquo;).<br />You should avoid alcohol while you are taking Venaxine XR.<br /><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should use Venaxine XR only after discussing the potential benefits and the potential risks to your unborn child with your doctor.<br />Make sure your midwife and/or doctor knows you are on Venaxine XR. When taken during pregnancy, similar drugs (SSRIs) may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish.<br />These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby you should contact your midwife and/or doctor immediately.<br />If you are taking this medicine during pregnancy, in addition to having trouble breathing, another symptom your baby might have when it is born is not feeding properly. If your baby has these symptoms when it is born and you are concerned, contact your doctor and/or midwife who will be able to advise you.<br />Venaxine XR passes into breast milk. There is a risk of an effect on the baby. Therefore, you should discuss the matter&nbsp;with your doctor, and he/she will decide whether you should stop breast-feeding or stop the therapy with this medicine.<br /><strong>Driving and using machines</strong><br />Do not drive or use any tools or machines until you know how this medicine affects you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.<br />The usual recommended starting dose for treatment of depression, generalised anxiety disorder and social anxiety disorder is 75 mg per day. The dose can be raised by your doctor gradually, and if needed, even up to a maximum dose of 375 mg daily for depression. If you are being treated for panic disorder, your doctor will start with a lower dose (37.5 mg) and then increase the dose gradually. The maximum dose for generalised anxiety disorder, social anxiety disorder and panic disorder is 225 mg/day.<br />Take Venaxine XR at approximately the same time each day, either in the morning or in the evening. Capsules must be swallowed whole with fluid and not opened, crushed, chewed or dissolved.<br />Venaxine XR should be taken with food.<br />If you have liver or kidney problems, talk to your doctor, since your dose of this medicine may need to be different.<br />Do not stop taking this medicine without talking to your doctor (see the section &ldquo;If you stop taking Venaxine XR&rdquo;).<br /><strong>If you take more Venaxine XR than you should</strong><br />Call your doctor or pharmacist immediately if you take more of this medicine than the amount prescribed by your doctor.<br />The symptoms of a possible overdose may include a rapid heart beat, changes in level of alertness (ranging from sleepiness to coma), blurred vision, seizures or fits, and<br />vomiting.<br /><strong>If you forget to take Venaxine XR</strong><br />If you miss a dose, take it as soon as you remember.<br />However, if it is time for your next dose, skip the missed dose and take only a single dose as usual. Do not take a double dose to make up for a forgotten dose. Do not take more than the daily amount of Venaxine XR that has been prescribed for you in one day.<br /><strong>If you stop taking Venaxine XR</strong><br />Do not stop taking your treatment or reduce the dose without the advice of your doctor even if you feel better. If your doctor thinks that you no longer need Venaxine XR, he/she may ask you to reduce your dose slowly before stopping treatment altogether. Side effects are known to occur when people stop using this medicine, especially when it is stopped suddenly or the dose is reduced too quickly. Some patients may experience symptoms such as tiredness, dizziness, light-headedness, headache, sleeplessness, nightmares, dry mouth, loss of appetite, nausea, diarrhoea, nervousness, agitation, confusion, ringing in the ears, tingling or rarely<br />electric shock sensations, weakness, sweating, seizures, or flu-like symptoms.<br />Your doctor will advise you on how you should gradually discontinue Venaxine XR treatment. If you experience any of these or other symptoms that are troublesome, ask your doctor for further advice.<br />If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.<br />If any of the following happen, do not take more Venaxine XR. Tell your doctor immediately, or go to the casualty department at your nearest hospital:<br /><strong>Uncommon (may affect up to 1 in 100 people)</strong></p><ul><li>Swelling of the face, mouth, tongue, throat, hands, or feet, and/or a raised itchy rash (hives), trouble swallowing or breathing</li></ul><p><strong>Frequency not known (cannot be estimated from the available data)</strong></p><ul><li>Chest tightness, wheezing, trouble swallowing or breathing</li><li>Severe skin rash, itching or hives (elevated patches of red or pale skin that often itch)</li><li>Signs and symptoms of serotonin syndrome which may include restlessness, hallucinations, loss of coordination, fast heart beat, increased body temperature, fast changes in blood pressure, overactive reflexes, diarrhoea, coma, nausea, vomiting. In its most severe form, serotonin syndrome can resemble Neuroleptic Malignant Syndrome (NMS). Signs and symptoms of NMS may include a combination of fever, fast heart beat, sweating, severe muscle stiffness, confusion, increased muscle enzymes (determined by a blood test).</li><li>Signs of infection, such as high temperature, chills, shivering, headaches, sweating, flu-like symptoms. This may be the result of a blood disorder which leads to an increased risk of infection.</li><li>Severe rash, which may lead to severe blistering and peeling of the skin.</li><li>Unexplained muscle pain, tenderness or weakness. This may be a sign of rhabdomyolysis</li></ul><p>Other side effects that you should tell your doctor about include (The frequency of these side effects are included in the list &ldquo;Other side effects that may occur&rdquo; below):</p><ul><li>Coughing, wheezing, shortness of breath and a high temperature</li><li>Black (tarry) stools or blood in stools</li><li>Itchiness, yellow skin or eyes, or dark urine, which may be symptoms of inflammation of the liver (hepatitis)</li><li>Heart problems, such as fast or irregular heart rate, increased blood pressure</li><li>Eye problems, such as blurred vision, dilated pupils</li><li>Nerve problems, such as dizziness, pins and needles, movement disorder, (muscle spasms or stiffness), seizures or fits</li><li>Psychiatric problems, such as hyperactivity and feeling unusually overexcited</li><li>Withdrawal effects (see the section &ldquo;How to take Venaxine XR, if you stop taking Venaxine XR&rdquo;).</li><li>Prolonged bleeding - if you cut or injure yourself, it may take slightly longer than usual for bleeding to stop.</li></ul><p><strong>Do not be concerned if you see small white balls or granules in your stools after taking this medicine. Inside Venaxine XR capsules are spheroids (small white balls)<br />that contain the active ingredient (venlafaxine). These spheroids are released from the capsule into your stomach. As they travel through your stomach and intestines, venlafaxine is slowly released. The spheroid &ldquo;shell&rdquo; does not dissolve and is passed out in your stools. So, even though you may see spheroids in your stools, your dose of medicine has been absorbed.</strong></p><p><strong><u>Other side effects that may occur<br />Very common (may affect more than 1 in 10 people)</u></strong></p><ul><li>Dizziness; headache</li><li>Nausea; dry mouth</li><li>Sweating (including night sweats)</li></ul><p><u><strong>Common (may affect up to 1 in 10 people)</strong></u></p><ul><li>Appetite decreased</li><li>Confusion; feeling separated (or detached) from yourself; lack of orgasm; decreased libido; nervousness; insomnia; abnormal dreams</li><li>Drowsiness; tremor; pins and needles; increased muscle tonus</li><li>Visual disturbance including blurred vision; dilated pupils; inability of the eye to automatically change focus from distant to near objects</li><li>Ringing in the ears (tinnitus)</li><li>Palpitations</li><li>Increase in blood pressure; flushing</li><li>Yawning</li><li>Vomiting; constipation; diarrhoea</li><li>Increased frequency in urination; difficulties passing urine</li><li>Menstrual irregularities such as increased bleeding or increased irregular bleeding; abnormal ejaculation/ orgasm (males); erectile dysfunction (impotence)</li><li>Weakness (asthenia); fatigue; chills</li><li>Increased cholesterol</li></ul><p><u><strong>Uncommon (may affect up to 1 in 100 people)</strong></u></p><ul><li>Hallucinations; feeling separated (or detached) from reality; agitation; abnormal orgasm (females); lack of feeling or emotion; feeling over-excited; grinding of the teeth</li><li>A sensation of restlessness or an inability to sit or stand still; fainting; involuntary movements of the muscles; impaired coordination and balance; altered taste sensation</li><li>Fast heartbeat; feeling dizzy (particularly when standing up too quickly)</li><li>Shortness of breath</li><li>Vomiting blood, black tarry stools (faeces) or blood in stools; which can be a sign of internal bleeding</li><li>Sensitivity to sunlight; bruising; rash; abnormal hair loss</li><li>Inability to pass urine;</li><li>Weight gain; weight loss</li></ul><p><u><strong>Rare (may affect up to 1 in 1,000 people)</strong></u></p><ul><li>Seizures or fits</li><li>Inability to control urination</li><li>Over activity, racing thoughts and decreased need for sleep (mania)</li></ul><p><u><strong>Frequency not known (cannot be estimated from the available data)</strong></u></p><ul><li>Prolonged bleeding, which may be a sign of reduced number of platelets in your blood, leading to an increased risk of bruising or bleeding</li><li>Excessive water intake (known as SIADH)</li><li>Decrease in blood sodium levels</li><li>Suicidal ideation and suicidal behaviours; cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy or early after treatment discontinuation (see section 2, , What you need to know before you take Venaxine XR)</li><li>Disorientation and confusion often accompanied by hallucination (delirium); aggression</li><li>Stiffness, spasms and involuntary movements of the muscles</li><li>Severe eye pain and decreased or blurred vision</li><li>Vertigo</li><li>Decrease in blood pressure; abnormal, rapid or irregular heart beat, which could lead to fainting; unexpected bleeding,&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; e.g. bleeding gums, blood in the urine or in vomit, or the appearance of unexpected bruises or broken blood vessels (broken veins)</li><li>Coughing, wheezing, shortness of breath and a high temperature, which are symptoms of inflammation of the lungs associated with an increase in white blood cells (pulmonary eosinophilia)</li><li>Severe abdominal or back pains (which could indicate a serious problem in the gut, liver or pancreas)</li><li>Itchiness, yellow skin or eyes, dark urine, or flu-like symptoms, which are symptoms of inflammation of the liver (hepatitis); slight changes in blood levels of liver enzymes</li><li>Itching; mild rash</li><li>Abnormal breast milk production</li></ul><p>Venaxine XR sometimes causes unwanted effects that you may not be aware of, such as increases in blood pressure or abnormal heart beat; slight changes in blood levels of liver enzymes, sodium or cholesterol. More rarely, Venaxine XR may reduce the function of platelets in your blood, leading to an increased risk of bruising or bleeding. Therefore, your doctor may wish to do blood tests occasionally, particularly if you have been taking Venaxine XR for a long time.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not use this medicine after the expiry date, which is stated on the packaging. The expiry date refers to the last day of that month.<br />Store below 30&deg;C.<br />Store in the original pack to protect from light and moisture.<br />Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help<br />protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Venaxine XR contains?</strong><br />Active ingredient: Each capsule contains:<br />Venlafaxine Hydrochloride (Ph. Eur) equivalent to Venlafaxine 75 mg.<br /><u>Other ingredients:</u><br />Povidone (K30), Isopropyl Alcohol, Calcium Hydrogen Phosphate (Di-Tab), Magnesium Stearate.<br />Coating material:<br />Ethyl Cellulose (N50Pharm), Hyperomellose, Isopropyl Alcohol, Methylene Chloride.<br /><br />&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                
Size ‘ 1 ‘ Capsules with peach coloured cap imprinted with ‘RC22’ and peach coloured body, containing eight white to off white mini tablets,
packed in Alu /PVC/PVDC- white blister, 14 Capsules/ Blister, 1 Blister per box.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</strong><br />P.O.Box 442, Riyadh 11411<br />Fax: +966 11 265 0505<br />Email: contact@riyadhpharma.com<br />For any information about this medicinal product, please contact the local representative of marketing authorisation holder:<br />Saudi Arabia<br />Marketing department<br />Riyadh<br />Tel: +966 11 265 0111<br />Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>فيناكسين إكس آر هو مضاد للاكتئاب الذي ينتمي إلى مجموعة من الأدوية تسمى مثبطات امتصاص السيروتونين والنورابينفرين (اس ان اراي). وتستخدم هذه المجموعة من الأدوية لعلاج الاكتئاب وحالات أخرى مثل اضطرابات القلق. ويعتقد أن الناس الذين هم مكتئبون و / أو قلقون لديهم مستويات منخفضة من السيروتونين والنورادرينالين في الدماغ. لا يفهم تماما كيفية عمل مضادات الاكتئاب، لكنها قد تساعد من خلال زيادة مستويات السيروتونين والنورادرينالين في الدماغ</p><p>فيناكسين إكس آر هو علاج للبالغين الذين يعانون من الاكتئاب. بل هو أيضا لعلاج البالغين الذين يعانون من اضطرابات القلق التالية: اضطراب القلق العام واضطراب القلق الاجتماعي (الخوف أو تجنب المواقف الاجتماعية) واضطراب الهلع (نوبات الهلع). علاج الاكتئاب أو اضطرابات القلق بشكل صحيح مهم لمساعدتك على التحسن. إذا لم يتم علاجها، حالتك قد لا تغادرك وربما تصبح أكثر خطورة وأكثر صعوبة للعلاج</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>أشياء مهمة يجب معرفتها حول فيناكسين إكس آر </strong></p><p>يرجى قراءة كل من هذه النشرة قبل البدء في تناول الدواء كما أنه يحتوي على معلومات هامة حول فيناكسين إكس آر</p><p><strong>&nbsp; &nbsp; &nbsp; &nbsp;&nbsp;</strong><strong>يستخدم فيناكسين إكس آر لعلاج الاكتئاب، والقلق الشديد والمستمر الذي يعرف باسم اضطراب القلق العام </strong><strong>، اضطراب القلق الاجتماعي (المعروف أيضا باسم الرهاب الاجتماعي)، واضطراب الهلع (نوبات الهلع</strong></p><p>&nbsp; &nbsp; &nbsp; &nbsp; &quot;<strong>فيناكسين إكس آر ليس للاستخدام في الأطفال والمراهقين</strong> &ndash; راجع في القسم 2 &quot;الأطفال والمراهقين</p><p><strong>إذا كان لديك أية مخاوف حول ما تشعر به، أو عن هذا الدواء، فمن المهم أن تتحدث مع طبيبك &ndash; حتى لو كنت تشعر بالتوتر أو القلق حول القيام بذلك</strong></p><p>قد تجد أنه من المفيد لإخبار صديق أو قريب أنك كنت مكتئبا أو تعاني من اضطرابات القلق، وأنه تم وصف هذا الدواء لك. قد يكون من المفيد أن تريهم هذه النشرة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قد لا يبدأ فيناكسين إكس آر للعمل فورا</strong>. بعض الأشخاص الذين يتناولون مضادات الاكتئاب قد يشعرون انهم أسوأ قبل الشعور بالتحسن. طبيبك قد يطلب رؤيتك مرة أخرى بضعة أسابيع بعد بدء العلاج وبعد ذلك بانتظام حتى تبدأ في الشعور بصحة جيدة ثانية. أخبر طبيبك إذا لم تبدأ في الشعور بالتحسن</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>بعض الناس الذين لديهم الاكتئاب قد يفكر في إيذاء أو قتل نفسه. وإذا حدث ذلك يجب مراجعة الطبيب أو الذهاب إلى المستشفى على الفور</strong> &ndash; راجع في القسم 2 &quot;التفكير في الانتحار وتفاقم الاكتئاب أو اضطراب القلق&nbsp;</p><p><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>إذا تناولت الكثير من كبسولات من المهم أن تحصل على مشورة طبية فورية، حتى لو كنت تشعر بصحة جيدة، بسبب خطر الآثار الجانبية الخطيرة</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>لا تتوقف عن تناول فيناكسين إكس آر أو تغيير الجرعة دون استشارة الطبيب الخاص بك حتى لو كنت تشعر بتحسن. </strong>إذا توقفت عن تناول فيناكسين إكس آر فجأة قد تحصل على ردود فعل الانسحاب &ndash; راجع قسم 3 &quot;إذا توقفت عن تناول فيناكسين إكس آر</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كان لديك مشاكل في القلب مثل معدل ضربات القلب السريعة أو غير المنتظم أو ارتفاع ضغط الدم يجب عليك التحدث مع طبيبك قبل اتخاذ فيناكسين إكس آر &ndash; </strong>راجع في القسم 2 &quot;<strong> </strong>ما يجب أن تعرفه قبل تناول فيناكسين إكس آر&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تناول بعض الأدوية الأخرى مع فيناكسين إكس آر قد يسبب مشاكل. يجب أن تخبر طبيبك إذا كنت تتناول أدوية </strong>أخرى &ndash; راجع في القسم 2 &#39;ما يجب أن تعرفه قبل تناول فيناكسين إكس آر&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>راجع الطبيب دون تأخير </strong>إذا كنت تشعر بقلق وتشعر وكأنك لا يمكن أن تبقي ثابتاً، أو تشعر &#39;بحالة معنوية عالية&#39; أو غاية في الحماسة، ولديك حركات العضلات متشنجة والتي لا يمكن السيطرة عليها. انظر القسم 4 &ndash;&quot;الآثار الجانبية المحتملة</p><p><strong>إذا كنتي حاملا، أو تنوين أن تصبحي حاملا، أو مرضعة، يجب عليك التحدث مع طبيبك</strong> &ndash; راجعي القسم 2 &quot;الحمل والرضاعة الطبيعية</p><p><strong>مزيد من المعلومات متوفر حول كل من هذه النقاط فيما تبقى من هذه النشرة</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:938px"><tbody><tr><td style="width:935px"><p><strong>الأفكار الانتحارية لدى الأطفال والمراهقين</strong></p><p><strong>زادت مضادات الاكتئاب من خطر التفكير في الانتحار وسلوكه (الانتحارية) في دراسات على المدى القصير في الأطفال والمراهقين يعانون من اضطراب الاكتئاب العام</strong><strong>&nbsp;&nbsp;</strong><strong>واضطرابات نفسية أخرى. أي شخص يفكر في استخدام فينلافاكسين إكس آر أو أي مضادات الاكتئاب الأخرى في طفل أو مراهق يجب أن يوازن بين هذه المخاطر وبين الحاجة الإكلينيكية. المرضى الذين بدأوا في العلاج يجب ملاحظتهم عن كثب من اجل ملاحظة التفاقم الإكلينيكي، الأفكار الانتحارية، أو تغييرات غير عادية في السلوك. ينبغي نصح الأسر ومقدمي الرعاية للحاجة إلى مراقبة وثيقة والتواصل مع واصف الدواء. لم تتم الموافقة على استخدام فينلافاكسين إكس آر في الأطفال المرضى. (انظر التنبيهات والتحذيرات، الاستخدام في الأطفال</strong></p><p><strong>في تحليل مجمع لتجارب بتحكم القياس مع العقار الوهمي قصيرة المدى (من 4 إلى 6 أسابيع) لـ 9 عقاقير مضادة للاكتئاب (إس إس أر أي وغيرها) في أطفال ومراهقين يعانون من اضطراب اكتئابي عام </strong><strong>&nbsp;ووسواس قهري </strong><strong>واضطرابات نفسية أخرى (ما مجموعه 24 تجربة اشترك بها 4400 مريض) نتجت عن خطر كبير للأعراض الجانبية الممثلة في التفكير أو السلوك الانتحاري (الانتحارية) خلال الشهور القليلة الأولى للعلاج للذين يتلقون مضادات الاكتئاب. معدل الخطورة لهذا الحدث في المرضى الذين يتلقون مضادات الاكتئاب كان 4% وهو ضعف معدل الخطورة للذين تلقوا العقار الوهمي بـ 2%. لم تحدث حالات انتحار في هذه التجارب</strong></p></td></tr></tbody></table><p><strong>لا تتناول فيناكسين إكس آر</strong></p><ul><li>إذا كان لديك حساسية من الفينلافاكسين أو أي من المكونات الأخرى من هذا الدواء (المدرجة في القسم&nbsp; 6</li><li>إذا كنت تتناول أيضا، أو قد تناولت في غضون الـ 14 يوما الماضية، أي أدوية معروفة باسم مثبطات أوكسيديز اللارجعية ، تستخدم لعلاج الاكتئاب أو مرض باركنسون. تناول (مثبطات م ا و )&nbsp;اللارجعية جنبا إلى جنب مع فيناكسين إكس آر، يمكن أن تتسبب في آثار جانبية خطيرة أو حتى قد تكون مهددة للحياة. أيضا، يجب الانتظار 7 أيام على الأقل بعد التوقف عن تناول فيناكسين إكس آر قبل تناول أي (مثبطات م ا و ) (انظر أيضا القسم المعنون &quot;أدوية الأخرى وفيناكسين إكس آر&quot; والمعلومات في هذا القسم حول &quot;متلازمة السيروتونين</li></ul><p><strong>التحذيرات والاحتياطات</strong></p><p>:تحدث إلى طبيبك أو الصيدلي قبل تناول فيناكسين إكس آر</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تستخدم الأدوية الأخرى التي تؤخذ جنبا إلى جنب مع فيناكسين إكس آر يمكن أن يزيد من خطر الاصابة بمتلازمة السيروتونين (راجع قسم &quot;أدوية الأخرى وفيناكسين إكس آر</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; (&nbsp;إذا كان لديك مشاكل في العين، مثل أنواع معينة من المياه الزرقاء (ارتفاع الضغط في العين</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من ارتفاع ضغط الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من مشاكل في القلب</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا قيل لك أن لديك إيقاع غير الطبيعي للقلب</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; (&nbsp;إذا كان لديك تاريخ من نوبات (تشنجات</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(إذا كان لديك تاريخ من انخفاض مستويات الصوديوم في الدم (نقص صوديوم الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك ميل لحدوث كدمات أو ميل للنزف بسهولة (تاريخ اضطرابات النزيف)، أو إذا كنت تتناول الأدوية الأخرى التي قد تزيد من خطر النزف على سبيل المثال، الوارفارين )(التي تستخدم لمنع تجلط الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ، أو إذا كان لدى شخص ما في عائلتك الهوس أو اضطراب ثنائي القطب (الشعور بالإفراط في التحمس أو الابتهاج</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك تاريخ من السلوك العنيف</p><p>فيناكسين إكس آر قد يسبب إحساس الأرق أو عدم القدرة على الجلوس أو الوقوف دون حراك خلال الأسابيع القليلة الأولى من العلاج. يجب إخبار الطبيب إذا حدث هذا لك</p><p><u>التفكير في الانتحار وتفاقم اضطراب الاكتئاب أو القلق الخاص بك</u></p><p>إذا كنت مكتئبا و / أو تعاني من اضطرابات القلق، يمكن أن يكون لديك في بعض الأحيان أفكار إيذاء أو قتل نفسك. ويمكن زيادة هذه عند أول بدء لتناول مضادات الاكتئاب، لأن هذه الادوية كلها تستغرق وقتا في العمل، عادة حوالي أسبوعين، وفي بعض الأحيان لفترة أطول</p><p>:قد تكون أكثر عرضة للتفكير من هذا القبيل</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك سبق الأفكار حول قتل نفسك أو إيذاء نفسك</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت من الشباب البالغين. أظهرت المعلومات المستقاة من التجارب السريرية زيادة مخاطر السلوك الانتحاري لدى البالغين من الشباب (أقل من 25 سنة) مع الحالات النفسية الذين عولجوا بمضاد للاكتئاب</p><p>إذا كان لديك أفكار إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور</p><p>قد تجد أنه من المفيد لإخبار صديق موثوق أو قريب أنك مكتئبا أو لديك اضطرابات القلق، واطلب منهم أن يقرأوا هذه النشرة. قد تطلب منهم أيضاً أن يخبروك إذا كانوا يعتقدون أن&nbsp;الاكتئاب أو القلق يزداد سوءا، أو إذا أنهم يشعرون بالقلق إزاء التغيرات في سلوكك</p><p><u>جفاف الفم</u></p><p>تشير التقارير أنه في 10٪ من المرضى الذين عولجوا بالفينلافاكسين يحدث جفاف الفم. وهذا قد يزيد من مخاطر تسوس الأسنان (التسويس). لذلك، يجب أن تهتم بالرعاية الخاصة لصحة أسنانك</p><p><u>داء السكري</u></p><p>قد يحدث تغيير مستويات السكر في الدم بسبب الفيناكسين إكس آر. لذلك، قد تحتاج إلى تعديل الجرعة من أدوية السكري</p><p><strong>الأطفال والمراهقين</strong></p><p>الفيناكسين إكس آر ينبغي عادة ألا يستخدم للأطفال والمراهقين دون سن 18 عاما. أيضا، يجب أن تعرف أن المرضى الذين تقل أعمارهم عن 18 لديهم خطر متزايد من الآثار الجانبية، مثل محاولة الانتحار، وأفكار انتحارية والعداء (بالدرجة الأولى العدوان، وسلوك المعارضة والغضب) عندما تتناول هذه الفئة من الأدوية. على الرغم من هذا، فإن طبيبك قد يصف هذا الدواء للمرضى دون سن 18 لأنه / أنها قرر أن هذا في مصلحتهم. إذا كان طبيبك قد وصف هذا الدواء للمريض تحت 18 سنة، وكنت ترغب في مناقشة هذا الموضوع، يرجى الرجوع إلى الطبيب. يجب إبلاغ الطبيب إذا كان أي من الأعراض المذكورة أعلاه تطور أو ازداد سوءا عند المرضى الذين تقل أعمارهم عن 18 ويتناولون الفيناكسين إكس آر. أيضا، لم تثبت آثار السلامة على المدى الطويل بشأن النمو والنضج والنمو الإدراكي والسلوكي من هذا الدواء في هذه الفئة العمرية</p><p><strong>الأدوية الأخرى وفيناكسين إكس آر</strong></p><p>أخبر طبيبك أو الصيدلي إذا كنت تتناول، قد اتخذت مؤخرا أو قد تأخذ أي أدوية أخرى</p><p>الطبيب هو الذي يقرر ما إذا كان يمكن تناول فيناكسين إكس آر مع أدوية أخرى</p><p>لا تبدأ أوتتوقف عن تناول أي أدوية، بما في ذلك تلك التي اشتريتها دون وصفة طبية، والعلاجات الطبيعية والعشبية، قبل التأكد مع طبيبك أو الصيدلي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مثبطات أوكسيديز التي تستخدم لعلاج الاكتئاب أو مرض باركنسون <strong>يجب ألا تؤخذ مع فيناكسين إكس آر</strong>. أخبر طبيبك إذا كنت قد تعاطيت هذه الأدوية في غضون 14 يوما الماضية. راجع المقطع &quot;ما يجب أن تعرفه قبل تناول فيناكسين إكس آر</p><p><strong>:متلازمة السيروتونين</strong></p><p>هي حالة ربما تهدد الحياة أو ردة فعل تشبه متلازمة الذهان الخبيثة راجع قسم &quot;الآثار الجانبية المحتملة&quot;)، قد تحدث مع العلاج بالفينلافاكسين، لا سيما عندما تتناوله مع أدوية أخرى</p><p>:الأمثلة على هذه الأدوية ما يلي</p><p>&nbsp; &nbsp; &nbsp; &nbsp;(أدوية التريبتان (التي تستخدم لالصداع النصفي</p><p>&nbsp; &nbsp; &nbsp; &nbsp;أدوية أخرى لعلاج الاكتئاب، وعلى سبيل المثال اس ان اراي، اس اس اراي، ثلاثية الحلقات، أو الأدوية التي تحتوي على الليثيوم</p><p>&nbsp; &nbsp; &nbsp; &nbsp;(الأدوية التي تحتوي على لينزوليد، مضاد حيوي (التي تستخدم لعلاج الالتهابات</p><p>&nbsp; &nbsp; &nbsp; الأدوية التي تحتوي على موكلوبميد(مثبطات م ا و)، والتي تستخدم لعلاج الاكتئاب</p><p>&nbsp; &nbsp; &nbsp; &nbsp;الأدوية التي تحتوي على سيبوترامين (التي تستخدم لانقاص الوزن</p><p>&nbsp; &nbsp; &nbsp; الأدوية التي تحتوي على ترامادول، فنتانيل، تابنتادول، البيثيدين، أو بنتازوسين (التي تستخدم لعلاج الألم الحاد</p><p>&nbsp; &nbsp; &nbsp; (الأدوية التي تحتوي على الديكستروميثورفان (التي تستخدم لعلاج السعال</p><p>&nbsp; &nbsp; &nbsp; الأدوية التي تحتوي على الميثادون (تستخدم لعلاج إدمان المخدرات المواد الأفيونية أو ألم شديد</p><p>&nbsp; &nbsp; &nbsp; &nbsp;الأدوية التي تحتوي على الميثيلين الأزرق (التي تستخدم لعلاج ارتفاع مستويات الميتيموغلوبين في الدم</p><p>&nbsp; &nbsp; &nbsp; &nbsp;المنتجات التي تحتوي على نبتة سانت جون (وتسمى أيضا بيرفوراتوم هيبريكام، علاج طبيعي أو عشبي مستخدم لعلاج الاكتئاب الخفيف</p><p>&nbsp; &nbsp; &nbsp;المنتجات التي تحتوي على التربتوفان (تستخدم لمشاكل مثل النوم والاكتئاب</p><p>&nbsp; &nbsp; مضادات الذهان (التي تستخدم لعلاج مرض يصحبه أعراض مثل سمع، أو رؤية أو تحسس أشياء ليست موجودة والمعتقدات الخاطئة، ارتياب غير عادي، الفهم الغير واضح ويصبح منسحباً</p><p>قد تشمل علامات وأعراض متلازمة السيروتونين خليط مما يلي: الأرق والهلوسة، وفقدان التنسيق، ضربات القلب السريعة، وزيادة درجة حرارة الجسم، وتغيرات سريعة في ضغط الدم، فرط نشاط ردود الفعل، والإسهال، والغيبوبة، والغثيان، والتقيؤفي أعنف صورها، يمكن ان تشبه متلازمة السيروتونين متلازمة الذهان الخبيثة&nbsp; قد تشمل علامات وأعراض خليط من الحمى، ضربات القلب السريعة، والتعرق، وتصلب العضلات الشديد، والارتباك، وزيادة إنزيمات العضلات (يتحدد عن طريق فحص الدم</p><p><strong>أخبر طبيبك فورا، أو اذهب إلى قسم الطوارئ في أقرب مستشفى لك إذا كنت تعتقد أن متلازمة السيروتونين تحدث لك</strong></p><p>يجب إخبار الطبيب إذا كنت تتناول الأدوية التي يمكن أن تؤثر على ضربات قلبك</p><p>:الأمثلة على هذه الأدوية ما يلي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات عدم انتظام ضربات القلب مثل الكينيدين اميودارون، سوتالول أو دوفيتيليد (التي تستخدم لعلاج عدم انتظام ضربات القلب</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الذهان مثل ثيوريدازين (انظر أيضا السيروتونين متلازمة أعلاه</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المضادات الحيوية مثل الاريثروميسين أو موكسيفلوكساسين (تستخدم لعلاج الالتهابات البكتيرية</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الهيستامين (التي تستخدم لعلاج الحساسية</p><p>:قد تتفاعل الأدوية التالية أيضا مع فيناكسين إكس آر ويجب استخدامها بحذر. فمن الأهمية أن تذكر إلى طبيبك أو الصيدلي إذا كنت تأخذ أدوية تحتوي على</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(الكيتوكونازول (دواء مضاد للفطريات</p><p>&middot;&nbsp; &nbsp; &nbsp; (&nbsp; &nbsp;هالوبيريدول أو ريسبيريدون (لعلاج الحالات النفسية</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp;(&nbsp; ميتوبرولول (حاصرات بيتا لعلاج ارتفاع ضغط الدم ومشاكل في القلب</p><p><strong>فيناكسين إكس آر مع الطعام والشراب والكحول</strong></p><p>ينبغي أن تؤخذ فيناكسين إكس آر مع الغذاء (انظر القسم 3 &quot;كيفية تناول فيناكسين إكس آر</p><p>يجب تجنب الكحول بينما تتناول فيناكسين إكس آر</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>إذا كنتي حاملا أو مرضعة، وتعتقدين أنك قد تكوني حاملا أو تخططين لإنجاب طفل، اسألي طبيبك أو الصيدلي للحصول على المشورة قبل تناول هذا الدواء. يجب عليك ألا تستخدمي فيناكسين إكس آر إلا بعد مناقشة الفوائد المحتملة والمخاطر المحتملة على الجنين مع طبيبك</p><p>تأكدي أن قابلتك و / أو الطبيب يعرف أنك تتناولين فيناكسين إكس آر. عندما تؤخذ العقاقير المماثلة (اس اس اراي) خلال فترة الحمل، قد تزيد من خطر حدوث حالة خطيرة في الأطفال، تسمى ارتفاع ضغط الدم الرئوي المستمر في حديثي الولادة&nbsp; مما يجعل الطفل يتنفس بشكل أسرع ويبدو مزرق. وعادة ما تبدأ هذه الأعراض خلال الـ 24 ساعة الأولى بعد ولادة الطفل. إذا حدث هذا لطفلك يجب عليك الاتصال بممرضة التوليد و / أو الطبيب على الفور</p><p>إذا كنتي تتناولين هذا الدواء خلال فترة الحمل، بالإضافة إلى أن طفلك عند ولادته لديه صعوبة في التنفس، وأعراض أخرى ولا يتغذى بشكل صحيح. إذا كان طفلك يعاني هذه الأعراض عند ولادته وكنتي قلقة، اتصلي بطبيبك و / أو القابلة الذي سوف يكون قادراً على تقديم المشورة لك</p><p>فيناكسين إكس آر يمر في حليب الثدي. هناك خطر من وجود أثر على الطفل. لذلك، يجب عليك مناقشة هذه المسألة مع طبيبك، وهو / هي سوف يقرر ما إذا كان يجب التوقف عن الرضاعة الطبيعية أو وقف العلاج مع هذا الدواء</p><p><strong>القيادة واستخدام الآلات</strong></p><p>لا تقد أو تستخدم أي أدوات أو آلات حتى تعرف كيف يؤثر هذا الدواء عليك</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائما هذا الدواء تماما كما اخبرك طبيبك. يجب عليك التحقق مع طبيبك أو الصيدلي إذا لم تكن متأكدا</p><p>جرعة البداية المعتادة الموصى بها لعلاج الاكتئاب، واضطراب القلق العام واضطراب القلق الاجتماعي هي 75 ملجم يوميا. الجرعة يمكن أن تزيد من قبل الطبيب تدريجيا، وإذا لزم الأمر، حتى إلى أن تصل إلى الجرعة القصوى من 375 ملجم يوميا لعلاج الاكتئاب. إذا كنت تعالج من اضطراب الهلع، طبيبك سوف يبدأ مع أقل جرعة (37.5 ملجم) ومن ثم زيادة الجرعة تدريجيا. والجرعة القصوى لاضطراب القلق العام واضطراب القلق الاجتماعي واضطراب الهلع هي 225 ملجم / يوم</p><p>خذ فيناكسين إكس آر في نفس الوقت تقريبا كل يوم، إما في الصباح أو في المساء. يجب أن تبتلع الكبسولات بأكملها مع السوائل بدون أن تفتحها، تسحقها، تمضغها أو تذيبها</p><p>ينبغي أن تتناول فيناكسين إكس آر مع الطعام</p><p>إذا كان لديك مشاكل في الكبد أو الكلى، تحدث مع طبيبك، لأن جرعة من هذا الدواء قد تحتاج إلى أن تكون مختلفة</p><p>لا تتوقف عن تناول هذا الدواء دون أن تتحدث مع طبيبك (انظر القسم &quot;إذا توقفت عن تناول فيناكسين إكس آر</p><p><strong>إذا تناولت أكثر مما يجب من فيناكسين إكس آر</strong></p><p>اتصل بطبيبك أو الصيدلي فورا إذا تناولت أكثر من هذا الدواء من الكمية الموصوفة من قبل طبيبك</p><p>قد تشمل أعراض الجرعة الزائدة الممكنة سرعة ضربات القلب، والتغيرات في مستوى اليقظة (بدءا من النعاس إلى الغيبوبة)، عدم وضوح الرؤية، وتشنجات أو نوبات، والقيء</p><p><strong>إذا نسيت أن تتناول فيناكسين إكس آر</strong></p><p>إذا فاتتك جرعة، تناولها حالما تتذكر. ومع ذلك، إذا كان الوقت قد حان لتناول جرعة تالية فتجاوز الجرعة المنسية وتناول فقط جرعة واحدة على النحو المعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. لا تتناول أكثر من الكمية اليومية من فيناكسين إكس آر الذي تم وصفه لك في يوم واحد</p><p><strong>إذا توقفت عن تناول فيناكسين إكس آر</strong></p><p>لا تتوقف عن تناول العلاج أو تقلل الجرعة دون استشارة الطبيب الخاص بك حتى لو كنت تشعر بتحسن. إذا ظن طبيبك أنك لم تعد بحاجة لفيناكسين إكس آر، فإنه / انها قد يطلب منك تقليل الجرعة ببطء قبل إيقاف العلاج تماما. ومن المعروف أن الآثار الجانبية تحدث عندما يتوقف الناس عن استخدام هذا الدواء، وخصوصا عند إيقافه فجأة أو تقليل الجرعة بسرعة كبيرة جدا. بعض المرضى قد يعانون من أعراض مثل التعب، الدوخة، والدوار الخفيف، والصداع، والأرق، والكوابيس، وجفاف الفم، فقدان الشهية، والغثيان، والإسهال، والعصبية، والتهيج، والارتباك، طنين في الأذنين، وخز أو نادرا إحساس الصدمات الكهربائية، ضعف، والتعرق، والتشنجات، أو أعراض شبيهة بأعراض الانفلونزا</p><p>سوف ينصحك طبيبك حول كيف ينبغي أن توقف علاج فيناكسين إكس آر تدريجيا. إذا كنت تواجه أي من هذه أو غيرها من الأعراض المزعجة، اسأل طبيبك لمزيد من المشورة</p><p>إذا كان لديك أي أسئلة أخرى عن كيفية استخدام هذا الدواء، اسأل طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، على الرغم من أنها لا تحدث للجميع</p><p>:إذا كان أي مما يلي يحدث، لا تتناول فيناكسين إكس آر أكثر من ذلك. <strong>أخبر طبيبك فورا، أو اذهب إلى قسم الطوارئ في أقرب مستشفى لك</strong></p><p><strong>(غير شائع (قد يؤثر على ما يصل إلى 1 في كل 100 شخص</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه والفم واللسان والحلق، واليدين، أو القدمين، و / أو طفح جلدي مرتفع وحكة (الشرى)، صعوبة في البلع أو التنفس</p><p><strong>(تردد غير معروفة (لا يمكن تقديرها من البيانات المتاحة</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضيق الصدر والأزيز، وصعوبة في البلع أو التنفس</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي شديد، والحكة أو الشرى (بقع مرتفعة من الجلد الأحمر أو الشاحب وفي كثير من الأحيان مع حكة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات وأعراض متلازمة السيروتونين التي قد تشمل الأرق والهلوسة، وفقدان التنسيق، ضربات القلب السريعة، وزيادة درجة حرارة الجسم، والتغيرات السريعة في ضغط الدم، وفرط نشاط ردود الفعل، والإسهال، والغيبوبة، والغثيان، والتقيؤ. في أعنف صورها، يمكن لمتلازمة السيروتونين أن تشابه متلازمة الذهان الخبيثة . قد تشمل علامات وأعراض&nbsp; خليط من الحمى، ضربات القلب السريعة، والتعرق، وتصلب العضلات الشديد، والارتباك، وزيادة إنزيمات العضلات (يتحدد عن طريق فحص الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; علامات العدوى، مثل ارتفاع درجة الحرارة، قشعريرة، الارتعاش، الصداع، والتعرق، وأعراض شبيهة بأعراض الانفلونزا. وهذا قد يكون نتيجة لاضطراب في الدم الأمر الذي يؤدي إلى زيادة خطر العدوى</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي الشديد، الذي قد يؤدي إلى ظهور تقرحات شديدة وتقشير الجلد</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام في العضلات غير المبرر أو أوجاع أو ضعف. قد يكون هذا دليلا على انحلال الربيدات بالعضلات</p><p>الآثار الجانبية الأخرى التي يجب أن تخبر طبيبك عنها تشمل (تم إدراج تردد الآثار الجانبية هذه في قائمة &quot;الآثار الجانبية الأخرى التي قد تحدث&quot; أدناه):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال والأزيز، وضيق في التنفس وارتفاع في درجة الحرارة</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; براز أسود (قطراني) أو الدم في البراز</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; (&nbsp;الحكة، إصفرار الجلد أو العينين، أو البول الداكن، والتي قد تكون أعراض التهاب الكبد (الالتهاب الكبدي</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل القلب، مثل سرعة أو عدم انتظام دقات القلب، وارتفاع ضغط الدم</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل العين، مثل عدم وضوح الرؤية، واتساع حدقة العين</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل الاعصاب، مثل الدوخة، والوخز والتنميل، واضطراب الحركة، (تقلص العضلات أو تصلبها)، تشنجات أو نوبات</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المشاكل النفسية، مثل فرط النشاط والشعور بالحماس الزائد بشكل غير عادي</p><p>&middot;&nbsp; &nbsp; &nbsp; &nbsp; &nbsp;(أعراض انسحاب (انظر القسم &quot;كيفية تناول فيناكسين إكس آر، إذا توقفت عن تناول فيناكسين إكس آر</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طول فترات النزيف &ndash; إذا حدث جرح أو إصابة لك، فإن النزيف قد يستغرق وقتا أطول قليلا من المعتاد حتى يتوقف</p><p><strong>لا تشعر بقلق إذا رأيت كرات أو حبيبات صغيرة بيضاء في البراز بعد تناول هذا الدواء. داخل كبسولات فيناكسين إكس آر أجسام شبه الكروية (كرات بيضاء صغيرة) التي تحتوي على المادة الفعالة (الفينلافاكسين). وتنطلق هذه الأجسام الشبه الكروية من الكبسولة إلى المعدة. أثناء رحلتها خلال المعدة والأمعاء، ينطلق ببطء الفينلافاكسين. و&quot;القشرة&quot; الكروية لا تذوب وتمر في البراز. لذلك، على الرغم من أنك قد ترى الأجسام الشبه الكروية في البراز، فلقد جرى امتصاص جرعتك من الدواء</strong></p><p><strong><u>الآثار الجانبية الأخرى التي قد تحدث</u></strong></p><p><strong><u>(شائعة جدا (قد تؤثر على أكثر من 1 في كل 10 اشخاص</u></strong></p><ul><li>دوخة. صداع الراس</li><li>الغثيان. فم جاف</li><li>التعرق (بما في ذلك تعرق ليلي)</li></ul><p><strong><u>(شائعة (قد يؤثر على ما يصل إلى 1 في كل 10 أشخاص</u></strong></p><ul><li>انخفاض الشهية</li><li>الارتباك. الشعور بالعزل (أو الانفصال) من نفسك؛ الافتقار إلى النشوة الجنسية. انخفاض الرغبة الجنسية. العصبية. الأرق؛ أحلام غير طبيعية</li><li>الخمول. الرجفة. وخز تنميل؛ ازدياد انقباضيه العضلات</li><li>اضطراب بصرية بما في ذلك عدم وضوح الرؤية. اتساع حدقة العين؛ عدم قدرة العين على تغيير تركيز النظر تلقائيا من البعد إلى الأجسام القريبة</li><li>رنين في الأذنين (الطنين)</li><li>الخفقان</li><li>زيادة في ضغط الدم. التوهج</li><li>التثاؤب</li><li>التقيؤ؛ إمساك، إسهال</li><li>زيادة تكرارالتبول. صعوبات في التبول</li><li>عدم انتظام الدورة الشهرية مثل زيادة النزيف أو زيادة النزيف غير المنتظم. القذف / نشوة الجماع غير طبيعية (ذكور)؛ عدم القدرة على الانتصاب (العجز الجنسي)</li><li>ضعف (الوهن)؛ التعب. قشعريرة برد</li><li>زيادة الكولسترول</li></ul><p><strong><u>(غير شائع (قد يؤثر على ما يصل إلى 1 في كل 100 شخص</u></strong></p><ul><li>الهلوسة. الشعور بالانعزال (أو الانفصال) عن الواقع. الإثارة. النشوة الجنسية غير طبيعية (إناث)؛ عدم وجود شعور أو عاطفة، الشعور بزيادة الحماس، طحن بالأسنان</li><li>احساس بالأرق أو عدم القدرة على الجلوس أو الوقوف دون حراك. إغماء؛ حركات لا إرادية للعضلات. وضعف التنسيق والتوازن. تغير حاسة التذوق &nbsp;</li><li>ضربات القلب السريعة. الشعور بالدوار (خاصة عند الوقوف بسرعة كبيرة جدا)</li><li>ضيق في التنفس</li><li>قيء الدم، براز أسود قطراني أو دم في البراز. والتي يمكن أن تكون علامة على حدوث نزيف داخلي</li><li><!--[if gte vml 1]><v:rect
      id="_x0000_s1026" style='position:absolute;left:0;text-align:left;
      margin-left:27pt;margin-top:-8.35pt;width:544.5pt;height:796.4pt;
      z-index:251661312;mso-position-horizontal-relative:page' o:allowincell="f"
      filled="f" strokeweight="1pt">
      <w:wrap anchorx="page"/>
     </v:rect><![endif]-->الحساسية لأشعة الشمس. كدمات. طفح جلدي. تساقط الشعر الغير طبيعي</li><li>عدم القدرة على التبول</li><li>زيادة الوزن؛ خسارة الوزن</li><li><p><strong><u>(نادر (قد يؤثر على ما يصل إلى 1 في كل 1،000 شخص</u></strong></p></li><li>التشنجات أو نوبات</li><li>عدم القدرة على التحكم في التبول</li><li>(نشاط أكثر، وتسابق الأفكار وقلة الحاجة الى النوم (الهوس</li><li><p><strong><u>(تردد غير معروفة (لا يمكن تقديرها من البيانات المتاحة</u></strong></p></li><li>النزيف لفترة طويلة، والذي قد يكون علامة على حدوث انخفاض عدد الصفائح الدموية في الدم، مما يؤدي إلى زيادة خطر الكدمات أو النزيف</li><li>(تناول الماء الزائد (المعروفة باسم</li><li>النقص في مستويات الصوديوم في الدم</li><li>التفكير في الانتحار والسلوكيات الانتحارية. وقد تم الإبلاغ عن حالات التفكير في الانتحار والسلوكيات الانتحارية خلال العلاج بفينلافاكسين أو في وقت مبكر بعد وقف علاج انظر القسم 2، ما تحتاج إلى معرفته قبل تناول فيناكسين إكس آر</li><li>الارتباك والحيرة كثيرا ما يكون مصحوبا بهلوسة (هذيان)؛ عدوان</li><li>التصلب، تشنجات وحركات لا إرادية للعضلات</li><li>ألم شديد في العين وانخفاض أو عدم وضوح الرؤية</li><li>الدوار</li><li>انخفاض في ضغط الدم. ضربات القلب غير طبيعية أوسريعة أو غير منتظمة، مما قد يؤدي إلى الإغماء. النزيف الغير متوقع، على سبيل المثال، نزيف اللثة، دم في البول أو في القيء، أو ظهور كدمات غير متوقعة أو الأوعية الدموية مكسورة (أوردة مكسورة</li><li>السعال والأزيز، وضيق في التنفس وارتفاع في درجة الحرارة، والتي هي أعراض التهاب الرئتين المرتبطة بزيادة في خلايا الدم البيضاء (فرط خلايا إيوزينوفل الرئوية</li><li>آلام في البطن أو الظهر شديدة (التي يمكن أن تشير إلى وجود مشكلة خطيرة في الأمعاء والكبد والبنكرياس</li><li>الحكة، اصفرار الجلد أو العينين والبول الداكن، أو أعراض تشبه اعراض الانفلونزا، والتي هي أعراض التهاب الكبد (الالتهاب الكبدي). تغييرات طفيفة في مستويات الدم من انزيمات الكبد</li><li>الحكة. طفح جلدي خفيف</li><li>إنتاج حليب الثدي الغير طبيعي</li><li><p>فيناكسين إكس آر يسبب أحيانا آثار غير مرغوب فيها والتي قد لا تكون معلومة، مثل زيادة ضغط الدم أو ضربات القلب غير طبيعية. تغييرات طفيفة في مستويات الدم من انزيمات الكبد، الصوديوم أو الكوليسترول. أكثر ندرة، قد يقلل فيناكسين إكس آر وظيفة الصفائح الدموية في الدم، مما يؤدي إلى زيادة خطر الكدمات أو النزيف. لذلك، قد يرغب الطبيب لإجراء اختبارات الدم في بعض الأحيان، خاصة إذا كنت تتناول فيناكسين إكس آر لفترة طويلة</p></li></ul>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ بعيدا عن متناول ومرأى الاطفال</p><p>يحفظ في درجة حرارة أقل من 30 درجة مئوية</p><p>يحفظ في العبوة الأصلية للحماية من الضوء والرطوبة</p><p>لا تستخدم فيناكسين إكس آر بعد تاريخ انتهاء الصلاحية المدون على العبوة، التاريخ يرجع إلى آخر يوم في هذا الشهر</p><p>يجب ألا يتم التخلص من الأدوية من خلال مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي كيفية التخلص من الأدوية التي لم تعد مطلوبة. سوف تساعد هذه التدابير لحماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;كل كبسولة تحتوي على</p><p><strong>فيناكسين إكس آر 75 ملجم</strong>: فينلافاكسين هيدروكلورايد (دستور الأدوية الأوروبي) أي ما يعادل فينلافاكسين 75 ملجم.<br /><em><u>مكونات أخرى</u></em><br /><em><u>:</u></em>البوفيدون، آيزوبروبيل الكحول، كالسيوم هيدروجين فوسفات ، مغنيسيوم استيارات</p><p>::مادة مغلفة</p><p>إيثيل السليلوز ، هيدروكسي بروبيل ميثيل سيللوز، آيزوبروبيل الكحول، كلوريد الميثيلي</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            فيناكسين إكس آر 75 ملجم: كبسولات حجم "1" مع غطاء بلون الخوخ مطبوع عليه "RC22" وجسم الكبسولة بلون الخوخ، وتحتوي على ثمانية أقراص صغيرة بيضاء إلى بيضاء داكنة، ومعبأة في شريط Alu /PVC/PVDC ابيض، 14 كبسولات / شريط، شريط واحد بالعلبة.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>(شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما</strong></p><p>.ص.ب.. 442 الرياض 11411</p><p>فاكس: 966112650505</p><p>contact@riyadhpharma.com :البريد الإلكتروني</p><p><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على صاحب الترخيص والتسويق</em></p><p>المملكة العربية السعودية</p><p>قسم التسويق</p><p>الرياض</p><p>تلفون: 966112650111</p><p>&nbsp;marketing@riyadhpharma.com :البريد الإلكتروني</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2017
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Venaxine XR 75 mg Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Venaxine XR 75 mg: each capsule contains 84.869 mg of Venlafaxine Hydrochloride (Ph. Eur) equivalent to 75 mg of Venlafaxine.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Extended release capsules
Venaxine XR 75 mg: Size ' 1 ' Capsules with peach coloured cap imprinted with 'RC22' and peach coloured body, containing eight white to off white  mini tablets, packed in Alu /PVC/PVDC- white blister, 14 Capsules/Blister, 1 Blister per box.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of major depressive episodes.</p><p>For prevention of recurrence of major depressive episodes.</p><p>Treatment of generalised anxiety disorder.</p><p>Treatment of social anxiety disorder.</p><p>Treatment of panic disorder, with or without agoraphobia.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><u>Major depressive episodes</u></p><p>The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 375 mg/day. Dosage increases can be made at intervals of 2 weeks or more. If clinically warranted due to symptom severity, dose increases can be made at more frequent intervals, but not less than 4 days.</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly on a case-by-case basis. Longer-term treatment may also be appropriate for prevention of recurrence of major depressive episodes (MDE). In most of the cases, the recommended dose in prevention of recurrence of MDE is the same as the one used during the current episode.</p><p>Antidepressive medicinal products should continue for at least six months following remission.</p><p><u>Generalised anxiety disorder</u></p><p>The recommended starting dose for prolonged-release venlafaxine is 75 mg given once daily. Patients not responding to the initial 75 mg/day dose may benefit from dose increases up to a maximum dose of 225 mg/day. Dosage increases can be made at intervals of 2 weeks or more.</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly, on a case-by-case basis.</p><p><u>Social anxiety disorder</u></p><p>The recommended dose for prolonged-release venlafaxine is 75 mg given once daily. There is no evidence that higher doses confer any additional benefit.</p><p>However, in individual patients not responding to the initial 75 mg/day, increases up to a maximum dose of 225 mg/day may be considered. Dosage increases can be made at intervals of 2 weeks or more.</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly, on a case-by-case basis.</p><p><u>Panic disorder</u></p><p>It is recommended that a dose of 37.5 mg/day of prolonged-release venlafaxine be used for 7 days. Dosage should then be increased to 75 mg/day. Patients not responding to the 75 mg/day dose may benefit from dose increases up to a maximum dose of 225 mg/day. Dosage increases can be made at intervals of 2 weeks or more.</p><p>Because of the risk of dose-related adverse effects, dose increments should be made only after a clinical evaluation (see section 4.4). The lowest effective dose should be maintained.</p><p>Patients should be treated for a sufficient period of time, usually several months or longer. Treatment should be reassessed regularly, on a case-by-case basis.</p><p><u>Elderly patients</u></p><p>No specific dose adjustments of venlafaxine are considered necessary based on patient age alone. However, caution should be exercised in treating the elderly (e.g., due to the possibility of renal impairment, the potential for changes in neurotransmitter sensitivity and affinity occurring with aging). The lowest effective dose should always be used, and patients should be carefully monitored when an increase in the dose is required.</p><p><u>Paediatric population</u></p><p>Venlafaxine is not recommended for use in children and adolescents.</p><p>Controlled clinical studies in children and adolescents with major depressive disorder failed to demonstrate efficacy and do not support the use of venlafaxine in these patients (see sections 4.4 and 4.8).</p><p>The efficacy and safety of venlafaxine for other indications in children and adolescents under the age of 18 have not been established.</p><p><u>Patients with hepatic impairment</u></p><p>In patients with mild and moderate hepatic impairment, in general a 50% dose reduction should be considered. However, due to inter-individual variability in clearance, individualisation of dosage may be desirable.</p><p>There are limited data in patients with severe hepatic impairment. Caution is advised, and a dose reduction by more than 50% should be considered. The potential benefit should be weighed against the risk in the treatment of patients with severe hepatic impairment.</p><p><u>Patients with renal impairment</u></p><p>Although no change in dosage is necessary for patients with glomerular filtration rate (GFR) between 30-70 ml/minute, caution is advised. For patients that require haemodialysis and in patients with severe renal impairment (GFR &lt; 30 ml/min), the dose should be reduced by 50%. Because of inter-individual variability in clearance in these patients, individualisation of dosage may be desirable.</p><p><u>Withdrawal symptoms seen on discontinuation of venlafaxine</u></p><p>Abrupt discontinuation should be avoided. When stopping treatment with venlafaxine, the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.</p><p><u>Method of administration</u></p><p>For oral use.</p><p>It is recommended that venlafaxine prolonged-release capsules be taken with food, at approximately the same time each day. Capsules must be swallowed whole with fluid and not divided, crushed, chewed, or dissolved.</p><p>Patients treated with venlafaxine immediate-release tablets may be switched to venlafaxine prolonged-release capsules at the nearest equivalent daily dosage. For example, venlafaxine immediate-release tablets 37.5 mg twice daily may be switched to venlafaxine prolonged-release capsules 75 mg once daily. Individual dosage adjustments may be necessary.</p><p>Venlafaxine prolonged-release capsules contain spheroids, which release the active substance slowly into the digestive tract. The insoluble portion of these spheroids is eliminated and may be seen in faeces.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Concomitant treatment with irreversible monoamine oxidase inhibitors (MAOIs) is contraindicated due to the risk of serotonin syndrome with symptoms such as agitation, tremor and hyperthermia. Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible MAOI.
Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible MAOI (see sections 4.4 and 4.5).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="1" cellpadding="1" style="width:872px"><tbody><tr><td style="width:869px"><p><strong>Boxed warning</strong></p><p><strong>Suicidality in Children and Adolescents </strong></p><p><strong>Antidepressants increased the risk of suicidal thinking and behavior (suicidality) in short-term studies in children and adolescents with Major Depressive Disorder (MDD) and other psychiatric disorders. Anyone considering the use of Venlafaxine XR or any other antidepressant in a child or adolescent must balance this risk with the clinical need. Patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Venlafaxine XR is not approved for use in pediatric patients. (See WARNINGS and PRECAUTIONS, Pediatric Use.) </strong></p><p><strong>Pooled analyses of short-term (4 to 16 weeks) placebo-controlled trials of 9 antidepressant drugs (SSRIs and others) in children and adolescents with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders (a total of 24 trials involving over 4400 patients) have revealed a greater risk of adverse events representing suicidal thinking or behavior (suicidality) during the first few months of treatment in those receiving antidepressants. The average risk of such events in patients receiving antidepressants was 4%, twice the placebo risk of 2%. No suicides occurred in these trials.</strong></p></td></tr></tbody></table><p><u>Suicide/suicidal thoughts or clinical worsening</u></p><p>Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery.</p><p>Other psychiatric conditions for which venlafaxine is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders.</p><p>Patients with a history of suicide-related events, or those exhibiting a significant degree of suicidal ideation prior to commencement of treatment, are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressant drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.</p><p>Close supervision of patients, and in particular those at high risk, should accompany drug therapy, especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour, and to seek medical advice immediately if these symptoms present.</p><p><u>Paediatric population</u></p><p>Efexor XL should not be used in the treatment of children and adolescents under the age of 18 years. Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly aggression, oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, long-term safety data in children and adolescents concerning growth, maturation and cognitive and behavioural development are lacking.</p><p><u>Serotonin syndrome</u></p><p>As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition may occur with venlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system (including triptans, SSRIs, SNRIs, lithium, sibutramine, St.John&#39;s Wort [<em>Hypericum perforatum</em>], fentanyl and its analogues, tramadol, dextromethorphan, tapentadol, pethidine, methadone and pentazocine), with medicinal agents that impair metabolism of serotonin (such as MAOIs e.g. methylene blue), with serotonin precursors (such as tryptophan supplements) or with antipsychotics or other dopamine antagonists (see sections 4.3 and 4.5).</p><p>Serotonin syndrome symptoms may include mental status changes (e.g., agitation, hallucinations, coma), autonomic instability (e.g., tachycardia, labile blood pressure, hyperthermia), neuromuscular aberrations (e.g., hyperreflexia, incoordination) and/or gastrointestinal symptoms (e.g., nausea, vomiting, diarrhoea). Serotonin syndrome in its most severe form, can resemble NMS, which includes hyperthermia, muscle rigidity, autonomic instability with possible rapid fluctuation of vital signs and mental status changes.</p><p>If concomitant treatment with venlafaxine and other agents that may affect the serotonergic and/or dopaminergic neurotransmitter systems is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.</p><p>The concomitant use of venlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended.</p><p><u>Narrow-angle glaucoma</u></p><p>Mydriasis may occur in association with venlafaxine. It is recommended that patients with raised intraocular pressure or patients at risk for acute narrow-angle glaucoma (angle-closure glaucoma) be closely monitored.</p><p><u>Blood pressure</u></p><p>Dose-related increases in blood pressure have been commonly reported with venlafaxine. In some cases, severely elevated blood pressure requiring immediate treatment has been reported in postmarketing experience. All patients should be carefully screened for high blood pressure and pre-existing hypertension should be controlled before initation of treatment. Blood pressure should be reviewed periodically, after initiation of treatment and after dose increases. Caution should be exercised in patients whose underlying conditions might be compromised by increases in blood pressure, e.g., those with impaired cardiac function.</p><p><u>Heart rate</u></p><p>Increases in heart rate can occur, particularly with higher doses. Caution should be exercised in patients whose underlying conditions might be compromised by increases in heart rate.</p><p><u>Cardiac disease and risk of arrhythmia</u></p><p>Venlafaxine has not been evaluated in patients with a recent history of myocardial infarction or unstable heart disease. Therefore, it should be used with caution in these patients.</p><p>In postmarketing experience, cases of QTc prolongation, Torsade de Pointes (TdP), ventricular tachycardia, and fatal cardiac arrhythmias have been reported with the use of venlafaxine, especially in overdose or in patients with other risk factors for QTc prolongation/TdP. The balance of risks and benefits should be considered before prescribing venlafaxine to patients at high risk of serious cardiac arrhythmia or QTc prolongation.</p><p><u>Convulsions</u></p><p>Convulsions may occur with venlafaxine therapy. As with all antidepressants, venlafaxine should be introduced with caution in patients with a history of convulsions, and concerned patients should be closely monitored. Treatment should be discontinued in any patient who develops seizures.</p><p><u>Hyponatraemia</u></p><p>Cases of hyponatraemia and/or the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) secretion may occur with venlafaxine. This has most frequently been reported in volume-depleted or dehydrated patients. Elderly patients, patients taking diuretics, and patients who are otherwise volume-depleted may be at greater risk for this event.</p><p><u>Abnormal bleeding</u></p><p>Medicinal products that inhibit serotonin uptake may lead to reduced platelet function. Bleeding events related to SSRI and SNRI use have ranged from ecchymoses, hematomas, epistaxis, and petechiae to gastrointestinal and life-threatening haemorrhages. The risk of haemorrhage may be increased in patients taking venlafaxine. As with other serotonin-reuptake inhibitors, venlafaxine should be used cautiously in patients predisposed to bleeding, including patients on anticoagulants and platelet inhibitors.</p><p><u>Serum cholesterol</u></p><p>Clinically relevant increases in serum cholesterol were recorded in 5.3% of venlafaxine-treated patients and 0.0% of placebo-treated patients treated for at least 3 months in placebo-controlled clinical trials. Measurement of serum cholesterol levels should be considered during long-term treatment.</p><p><u>Co-administration with weight loss agents</u></p><p>The safety and efficacy of venlafaxine therapy in combination with weight loss agents, including phentermine, have not been established. Co-administration of venlafaxine and weight loss agents is not recommended. Venlafaxine is not indicated for weight loss alone or in combination with other products.</p><p><u>Mania/hypomania</u></p><p>Mania/hypomania may occur in a small proportion of patients with mood disorders who have received antidepressants, including venlafaxine. As with other antidepressants, venlafaxine should be used cautiously in patients with a history or family history of bipolar disorder.</p><p><u>Aggression</u></p><p>Aggression may occur in a small number of patients who have received antidepressants, including venlafaxine. This has been reported under initiation, dose changes and discontinuation of treatment.</p><p>As with other antidepressants, venlafaxine should be used cautiously in patients with a history of aggression.</p><p><u>Discontinuation of treatment</u></p><p>Withdrawal symptoms, when treatment is discontinued, are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, adverse events seen on treatment discontinuation (tapering and post-tapering) occurred in approximately 31% of patients treated with venlafaxine and 17% of patients taking placebo.</p><p>The risk of withdrawal symptoms may be dependent on several factors, including the duration and dose of therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions. Generally, these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment, but there have been very rare reports of such symptoms in patients who have inadvertently missed a dose. Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that venlafaxine should be gradually tapered when discontinuing treatment over a period of several weeks or months, according to the patient&#39;s needs (see section 4.2).</p><p><u>Akathisia/psychomotor restlessness</u></p><p>The use of venlafaxine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p><u>Dry mouth</u></p><p>Dry mouth is reported in 10% of patients treated with venlafaxine. This may increase the risk of caries, and patients should be advised upon the importance of dental hygiene.</p><p><u>Diabetes</u></p><p>In patients with diabetes, treatment with an SSRI or venlafaxine may alter glycaemic control. Insulin and/or oral antidiabetic dosage may need to be adjusted.</p><p><em>Drug-Laboratory Test Interactions</em></p><p>False-positive urine immunoassay screening tests for phencyclidine (PCP) and amphetamine have been reported in patients taking venlafaxine. This is due to lack of specificity of the screening tests. False positive test results may be expected for several days following discontinuation of venlafaxine therapy. Confirmatory tests, such as gas chromatography/mass spectrometry, will distinguish venlafaxine from PCP and amphetamine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;<u>Monoamine Oxidase Inhibitors (MAOI)</u></p><p><em>Irreversible non-selective MAOIs</em></p><p>Venlafaxine must not be used in combination with irreversible non-selective MAOIs. Venlafaxine must not be initiated for at least 14 days after discontinuation of treatment with an irreversible non-selective MAOI. Venlafaxine must be discontinued for at least 7 days before starting treatment with an irreversible non-selective MAOI (see sections 4.3 and 4.4).</p><p><em>Reversible, selective MAO-A inhibitor (moclobemide)</em></p><p>Due to the risk of serotonin syndrome, the combination of venlafaxine with a reversible and selective MAOI, such as moclobemide, is not recommended. Following treatment with a reversible MAO-inhibitor, a shorter withdrawal period than 14 days may be used before initiation of venlafaxine treatment. It is recommended that venlafaxine should be discontinued for at least 7 days before starting treatment with a reversible MAOI (see section 4.4).</p><p><em>Reversible, non-selective MAOI (linezolid)</em></p><p>The antibiotic linezolid is a weak reversible and non-selective MAOI and should not be given to patients treated with venlafaxine (see section 4.4).</p><p>Severe adverse reactions have been reported in patients who have recently been discontinued from an MAOI and started on venlafaxine, or have recently had venlafaxine therapy discontinued prior to initiation of an MAOI. These reactions have included tremor, myoclonus, diaphoresis, nausea, vomiting, flushing, dizziness, and hyperthermia with features resembling neuroleptic malignant syndrome, seizures, and death.</p><p><u>Serotonin syndrome</u></p><p>As with other serotonergic agents, serotonin syndrome, a potentially life-threatening condition, may occur with venlafaxine treatment, particularly with concomitant use of other agents that may affect the serotonergic neurotransmitter system (including triptans, SSRIs, SNRIs, lithium, sibutramine, St. John&#39;s Wort [<em>Hypericum perforatum</em>], fentanyl and its analogues, tramadol, dextromethorphan, tapentadol, pethidine, methadone and pentazocine), with medicinal agents that impair metabolism of serotonin (such as MAOIs e.g. methylene blue), with serotonin precursors (such as tryptophan supplements) or with antipsychotics or other dopamine antagonists (see sections 4.3 and 4.4).</p><p>If concomitant treatment with venlafaxine and an SSRI, an SNRI or a serotonin receptor agonist (triptan) is clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases. The concomitant use of venlafaxine with serotonin precursors (such as tryptophan supplements) is not recommended (see section 4.4).</p><p><u>CNS-active substances</u></p><p>The risk of using venlafaxine in combination with other CNS-active substances has not been systematically evaluated. Consequently, caution is advised when venlafaxine is taken in combination with other CNS-active substances.</p><p><u>Ethanol</u></p><p>Venlafaxine has been shown not to increase the impairment of mental and motor skills caused by ethanol. However, as with all CNS-active substances, patients should be advised to avoid alcohol consumption.</p><p><u>Drugs that Prolong the QT Interval</u></p><p>The risk of QTc prolongation and/or ventricular arrhythmias (e.g., TdP) is increased with concomitant use of other medicinal products which prolong the QTc interval. Co-administration of such medicinal products should be avoided (see section 4.4).</p><p>Relevant classes include:</p><p>&bull; class Ia and III antiarrhythmics (e.g. quinidine, amiodarone, sotalol, dofetilide)</p><p>&bull; some antipsychotics (e.g. thioridazine)</p><p>&bull; some macrolides (e.g. erythromycin)</p><p>&bull; some antihistamines</p><p>&bull; some quinolone antibiotics (e.g. moxifloxacin)</p><p>The above list is not exhaustive and other individual medicinal products known to significantly increase QT interval should be avoided.</p><p><u>Effect of other medicinal products on venlafaxine</u></p><p><em>Ketoconazole (CYP3A4 inhibitor)</em></p><p>A pharmacokinetic study with ketoconazole in CYP2D6 extensive (EM) and poor metabolisers (PM) resulted in higher AUC of venlafaxine (70% and 21% in CYP2D6 PM and EM subjects, respectively) and O-desmethylvenlafaxine (33% and 23% in CYP2D6 PM and EM subjects, respectively) following administration of ketoconazole. Concomitant use of CYP3A4 inhibitors (e.g., atazanavir, clarithromycin, indinavir, itraconazole, voriconazole, posaconazole, ketoconazole, nelfinavir, ritonavir, saquinavir, telithromycin) and venlafaxine may increase levels of venlafaxine and O-desmethylvenlafaxine. Therefore, caution is advised if a patient&#39;s therapy includes a CYP3A4 inhibitor and venlafaxine concomitantly.</p><p><u>Effect of venlafaxine on other medicinal products</u></p><p><em>Lithium</em></p><p>Serotonin syndrome may occur with the concomitant use of venlafaxine and lithium (see Serotonin syndrome).</p><p><em>Diazepam</em></p><p>Venlafaxine has no effects on the pharmacokinetics and pharmacodynamics of diazepam and its active metabolite, desmethyldiazepam. Diazepam does not appear to affect the pharmacokinetics of either venlafaxine or O-desmethylvenlafaxine. It is unknown whether a pharmacokinetic and/or pharmacodynamic interaction with other benzodiazepines exists.</p><p><em>Imipramine</em></p><p>Venlafaxine did not affect the pharmacokinetics of imipramine and 2-OH-imipramine. There was a dose-dependent increase of 2-OH-desipramine AUC by 2.5 to 4.5-fold when venlafaxine 75 mg to 150 mg daily was administered. Imipramine did not affect the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine. The clinical significance of this interaction is unknown. Caution should be exercised with co-administration of venlafaxine and imipramine.</p><p><em>Haloperidol</em></p><p>A pharmacokinetic study with haloperidol has shown a 42% decrease in total oral clearance, a 70% increase in AUC, an 88% increase in C<sub>max</sub>, but no change in half-life for haloperidol. This should be taken into account in patients treated with haloperidol and venlafaxine concomitantly. The clinical significance of this interaction is unknown.</p><p><em>Risperidone</em></p><p>Venlafaxine increased the risperidone AUC by 50%, but did not significantly alter the pharmacokinetic profile of the total active moiety (risperidone plus 9-hydroxyrisperidone). The clinical significance of this interaction is unknown.</p><p><em>Metoprolol</em></p><p>Concomitant administration of venlafaxine and metoprolol to healthy volunteers in a pharmacokinetic interaction study for both medicinal products resulted in an increase of plasma concentrations of metoprolol by approximately 30-40% without altering the plasma concentrations of its active metabolite, &alpha;-hydroxymetoprolol. The clinical relevance of this finding in hypertensive patients is unknown. Metoprolol did not alter the pharmacokinetic profile of venlafaxine or its active metabolite, O-desmethylvenlafaxine. Caution should be exercised with co-administration of venlafaxine and metoprolol.</p><p><em>Indinavir</em></p><p>A pharmacokinetic study with indinavir has shown a 28% decrease in AUC and a 36% decrease in C<sub>max</sub>&nbsp;for indinavir. Indinavir did not affect the pharmacokinetics of venlafaxine and O-desmethylvenlafaxine. The clinical significance of this interaction is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>FDA&nbsp;Pregnancy Category&nbsp;C</p><p>There are no adequate data from the use of venlafaxine in pregnant women.</p><p>Studies in animals have shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Venlafaxine must only be administered to pregnant women if the expected benefits outweigh any possible risk.</p><p>As with other serotonin reuptake inhibitors (SSRIs/SNRIs), discontinuation symptoms may occur in the newborns if venlafaxine is used until or shortly before birth. Some newborns exposed to venlafaxine late in the third trimester have developed complications requiring tube-feeding, respiratory support or prolonged hospitalisation. Such complications can arise immediately upon delivery.</p><p>Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). Although no studies have investigated an association of PPHN to SNRI treatment, this potential risk cannot be ruled out with venlafaxine taking into account the related mechanism of action (inhibition of the re-uptake of serotonin).</p><p>The following symptoms may be observed in neonates if the mother has used an SSRI/SNRI late in pregnancy: irritability, tremor, hypotonia, persistent crying, and difficulty in sucking or in sleeping. These symptoms may be due to either serotonergic effects or exposure symptoms. In the majority of cases, these complications are observed immediately or within 24 hours after partus.</p><p><strong><u>Breastfeeding</u></strong></p><p>Venlafaxine and its active metabolite, O-desmethylvenlafaxine, are excreted in breast milk. There have been post-marketing reports of breast-fed infants who experienced crying, irritability, and abnormal sleep patterns. Symptoms consistent with venlafaxine drug discontinuation have also been reported after stopping breast-feeding. A risk to the suckling child cannot be excluded. Therefore, a decision to continue/discontinue breast-feeding or to continue/discontinue therapy with Efexor XL should be made, taking into account the benefit of breast-feeding to the child and the benefit of Efexor XL therapy to the woman.</p><p><strong><u>Fertility</u></strong></p><p>Reduced fertility was observed in a study in which both male and female rats were exposed to O-desmethylvenlafaxine. The human relevance of this finding is unknown (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any psychoactive medicinal product may impair judgment, thinking, and motor skills. Therefore, any patient receiving venlafaxine should be cautioned about their ability to drive or operate hazardous machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;<u>Summary of the safety profile</u></p><p>The most commonly (&gt;1/10) reported adverse reactions in clinical studies were nausea, dry mouth, headache and sweating (including night sweats).</p><p><u>Tabulated list of adverse reactions</u></p><p>Adverse reactions are listed below by system organ class and frequency.</p><p>Frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Body System</strong></p></td><td style="vertical-align:top"><p><strong>Very Common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Thrombocytopaenia, Blood disorder, (including agranulocytosis, aplastic anaemia, neutropaenia, pancytopaenia)</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anaphylactic reaction</p></td></tr><tr><td style="vertical-align:top"><p>Endocrine disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Syndrome of Inappropriate antidiuretic hormone secretion (SIADH)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Confusional state, Depersonalization, Anorgasmia, Libido decreased, Nervousness, Insomnia, Abnormal dreams</p></td><td style="vertical-align:top"><p>Hallucination, Derealization, Agitation, Orgasm abnormal (female), Apathy, Hypomania, Bruxism</p></td><td style="vertical-align:top"><p>Mania</p></td><td style="vertical-align:top"><p>Suicidal ideation and suicidal behaviours*, Delirium, Aggression**</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p><p>Headache***</p></td><td style="vertical-align:top"><p>Somnolence, Tremor, Paraesthesia, Hypertonia</p></td><td style="vertical-align:top"><p>Akathisia/ Psychomotor restlessness, Syncope, Myoclonus, Coordination abnormal, Balance disorder, Dysgeusia</p></td><td style="vertical-align:top"><p>Convulsion,</p></td><td style="vertical-align:top"><p>Neuroleptic Malignant Syndrome (NMS), Serotonergic syndrome, Extrapyramidal disorder, including dystonia and dyskinaesia, Tardive dyskinaesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual impairment, including vision blurred, Mydriasis, Accommodation disorder</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angle-closure glaucoma</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Tachycardia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Ventricular fibrillation, Ventricular tachycardia (including Torsade de Pointes)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypertension, Vasodilatation (mostly flush)</p></td><td style="vertical-align:top"><p>Orthostatic hypotension,</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension, Bleeding (mucous membrane bleeding)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Yawning</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pulmonary eosinophilia</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Nausea, Dry mouth</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Diarrhoea, Constipation</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hepatitis, Liver function test abnormal</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Hyperhidrosis (including night sweats)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema, Photosensitivity reaction, Ecchymosis, Rash, Alopecia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Erythema multiforme, Toxic epidermal necrolysis, Stevens-Johnson syndrome, Pruritus, Urticaria</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dysuria (mostly urinary hesitation), Pollakiuria</p></td><td style="vertical-align:top"><p>Urinary retention</p></td><td style="vertical-align:top"><p>Urinary incontinence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Menstrual disorders associated with increased bleeding or irregular bleeding (e.g. menorrhagia, metrorrhagia), Ejaculation disorder, Erectile dysfunction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Asthenia, Fatigue, Chills</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood cholesterol increased</p></td><td style="vertical-align:top"><p>Weight increased, Weight decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Electrocardiogram QT prolonged, Bleeding time prolonged, Blood prolactin increased</p></td></tr></tbody></table><p>* Cases of suicidal ideation and suicidal behaviours have been reported during venlafaxine therapy or early after treatment discontinuation (see section 4.4).</p><p>** See section 4.4</p><p>***In pooled clinical trials, the incidence of headache with venlafaxine and placebo were similar.</p><p><u>Discontinuation of treatment</u></p><p>Discontinuation of venlafaxine (particularly when abrupt) commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraethesia), sleep disturbances (including insomnia and intense dreams), agitation or anxiety, nausea and/or vomiting, tremor, vertigo, headache and flu syndrome are the most commonly reported reactions. Generally, these events are mild to moderate and are self-limiting; however, in some patients, they may be severe and/or prolonged. It is therefore advised that when venlafaxine treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p><u>Paediatric population</u></p><p>In general, the adverse reaction profile of venlafaxine (in placebo-controlled clinical trials) in children and adolescents (ages 6 to 17) was similar to that seen for adults. As with adults, decreased appetite, weight loss, increased blood pressure, and increased serum cholesterol were observed (see section 4.4).</p><p>In paediatric clinical trials the adverse reaction suicidal ideation was observed. There were also increased reports of hostility and, especially in major depressive disorder, self-harm.</p><p>Particularly, the following adverse reactions were observed in paediatric patients: abdominal pain, agitation, dyspepsia, ecchymosis, epistaxis, and myalgia.</p><p><strong>To report any side effects</strong></p><p>- National Pharmacovigilance and Drug Safety Center (NPC)</p><ul><li>Fax: +966-11-205-7662</li><li>To call the executive management of vigilance and crisis management: +966-11-2038222 ext.: 2353 &ndash; 2356 &ndash; 2317 &ndash; 2354 &ndash; 2334 &ndash; 2340</li><li>Toll-free: 8002490000</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: www.sfda.gov.sa/npc</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In postmarketing experience, overdose with venlafaxine was reported predominantly in combination with alcohol and/or other medicinal products. The most commonly reported events in overdose include tachycardia, changes in level of consciousness (ranging from somnolence to coma), mydriasis, convulsion, and vomiting. Other reported events include electrocardiographic changes (e.g., prolongation of QT interval, bundle branch block, QRS prolongation), ventricular tachycardia, bradycardia, hypotension, vertigo, and deaths.</p><p>Published retrospective studies report that venlafaxine overdosage may be associated with an increased risk of fatal outcomes compared to that observed with SSRI antidepressant products, but lower than that for tricyclic antidepressants. Epidemiological studies have shown that venlafaxine-treated patients have a higher burden of suicide risk factors than SSRI patients. The extent to which the finding of an increased risk of fatal outcomes can be attributed to the toxicity of venlafaxine in overdosage, as opposed to some characteristics of venlafaxine-treated patients, is not clear. Prescriptions for venlafaxine should be written for the smallest quantity of the medicinal product consistent with good patient management in order to reduce the risk of overdose.</p><p><u>Recommended treatment</u></p><p>General supportive and symptomatic measures are recommended; cardiac rhythm and vital signs must be monitored. When there is a risk of aspiration, induction of emesis is not recommended. Gastric lavage may be indicated if performed soon after ingestion or in symptomatic patients. Administration of activated charcoal may also limit absorption of the active substance. Forced diuresis, dialysis, hemoperfusion and exchange transfusion are unlikely to be of benefit. No specific antidotes for venlafaxine are known.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other antidepressants - ATC code: NO6A X16.</p><p><strong><u>Mechanism of action</u></strong></p><p>The mechanism of venlafaxine&#39;s antidepressant action in humans is believed to be associated with its potentiation of neurotransmitter activity in the central nervous system. Preclinical studies have shown that venlafaxine and its major metabolite, O-desmethylvenlafaxine (ODV), are inhibitors of serotonin and noradrenaline reuptake. Venlafaxine also weakly inhibits dopamine uptake. Venlafaxine and its active metabolite reduce &beta;-adrenergic responsiveness after both acute (single dose) and chronic administration. Venlafaxine and ODV are very similar with respect to their overall action on neurotransmitter reuptake and receptor binding.</p><p>Venlafaxine has virtually no affinity for rat brain muscarinic, cholinergic, H<sub>1</sub>-histaminergic or &alpha;<sub>1</sub>-adrenergic receptors&nbsp;<em>in vitro</em>. Pharmacological activity at these receptors may be related to various side effects seen with other antidepressant medicinal products, such as anticholinergic, sedative and cardiovascular side effects.</p><p>Venlafaxine does not possess monoamine oxidase (MAO) inhibitory activity.</p><p><em>In vitro</em>&nbsp;studies revealed that venlafaxine has virtually no affinity for opiate or benzodiazepine sensitive receptors.</p><p><u>Clinical efficacy and safety</u></p><p><u>Major depressive episodes</u></p><p>The efficacy of venlafaxine immediate-release as a treatment for major depressive episodes was demonstrated in five randomised, double-blind, placebo-controlled, short-term trials ranging from 4 to 6 weeks duration, for doses up to 375 mg/day. The efficacy of venlafaxine prolonged-release as a treatment for major depressive episodes was established in two placebo-controlled, short-term studies for 8 and 12 weeks duration, which included a dose range of 75 to 225 mg/day.</p><p>In one longer-term study, adult outpatients who had responded during an 8-week open trial on venlafaxine prolonged-release (75, 150, or 225 mg) were randomised to continuation of their same venlafaxine prolonged-release dose or to placebo, for up to 26 weeks of observation for relapse.</p><p>In a second longer-term study, the efficacy of venlafaxine in prevention of recurrent depressive episodes for a 12-month period was established in a placebo-controlled double-blind clinical trial in adult outpatients with recurrent major depressive episodes who had responded to venlafaxine treatment (100 to 200 mg/day, on a b.i.d. schedule) on the last episode of depression.</p><p><u>Generalised anxiety disorder</u></p><p>The efficacy of venlafaxine prolonged-release capsules as a treatment for generalised anxiety disorder (GAD) was established in two 8-week, placebo-controlled, fixed-dose studies (75 to 225 mg/day), one 6-month, placebo-controlled, fixed-dose study (75 to 225 mg/day), and one 6-month, placebo-controlled, flexible-dose study (37.5, 75, and 150 mg/day) in adult outpatients.</p><p>While there was also evidence for superiority over placebo for the 37.5 mg/day dose, this dose was not as consistently effective as the higher doses.</p><p><u>Social anxiety disorder</u></p><p>The efficacy of venlafaxine prolonged-release capsules as a treatment for social anxiety disorder was established in four double-blind, parallel-group, 12-week, multi-center, placebo-controlled, flexible-dose studies and one double-blind, parallel-group, 6-month, placebo-controlled, fixed/flexible-dose study in adult outpatients. Patients received doses in a range of 75 to 225 mg/day. There was no evidence for any greater effectiveness of the 150 to 225 mg/day group compared to the 75 mg/day group in the 6-month study.</p><p><u>Panic disorder</u></p><p>The efficacy of venlafaxine prolonged-release capsules as a treatment for panic disorder was established in two double-blind, 12-week, multi-center, placebo-controlled studies in adult outpatients with panic disorder, with or without agoraphobia. The initial dose in panic disorder studies was 37.5 mg/day for 7 days. Patients then received fixed doses of 75 or 150 mg/day in one study and 75 or 225 mg/day in the other study.</p><p>Efficacy was also established in one long-term double-blind, placebo-controlled, parallel-group study of the long-term safety, efficacy, and prevention of relapse in adult outpatients who responded to open-label treatment. Patients continued to receive the same dose of venlafaxine prolonged-release that they had taken at the end of the open-label phase (75, 150, or 225 mg).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Venlafaxine is extensively metabolised, primarily to the active metabolite, O-desmethylvenlafaxine (ODV). Mean &plusmn; SD plasma half-lives of venlafaxine and ODV are 5&plusmn;2 hours and 11&plusmn;2 hours, respectively. Steady-state concentrations of venlafaxine and ODV are attained within 3 days of oral multiple-dose therapy. Venlafaxine and ODV exhibit linear kinetics over the dose range of 75 mg to 450 mg/day.</p><p><u>Absorption</u></p><p>At least 92% of venlafaxine is absorbed following single oral doses of immediate-release venlafaxine. Absolute bioavailability is 40% to 45% due to presystemic metabolism. After immediate-release venlafaxine administration, the peak plasma concentrations of venlafaxine and ODV occur in 2 and 3 hours, respectively. Following the administration of venlafaxine prolonged-release capsules, peak plasma concentrations of venlafaxine and ODV are attained within 5.5 hours and 9 hours, respectively. When equal daily doses of venlafaxine are administered as either an immediate-release tablet or prolonged-release capsule, the prolonged-release capsule provides a slower rate of absorption, but the same extent of absorption compared with the immediate-release tablet. Food does not affect the bioavailability of venlafaxine and ODV.</p><p><u>Distribution</u></p><p>Venlafaxine and ODV are minimally bound at therapeutic concentrations to human plasma proteins (27% and 30%, respectively). The volume of distribution for venlafaxine at steady-state is 4.4&plusmn;1.6 L/kg following intravenous administration.</p><p><u>Biotransformation</u></p><p>Venlafaxine undergoes extensive hepatic metabolism.&nbsp;<em>In vitro</em>&nbsp;and in vivo studies indicate that venlafaxine is biotransformed to its major active metabolite, ODV, by CYP2D6.&nbsp;<em>In vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;studies indicate that venlafaxine is metabolised to a minor, less active metabolite, N-desmethylvenlafaxine, by CYP3A4.&nbsp;<em>In vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;studies indicate that venlafaxine is a weak inhibitor of CYP2D6. Venlafaxine did not inhibit CYP1A2, CYP2C9, or CYP3A4.</p><p><u>Elimination</u></p><p>Venlafaxine and its metabolites are excreted primarily through the kidneys. Approximately 87% of a venlafaxine dose is recovered in the urine within 48 hours as either unchanged venlafaxine (5%), unconjugated ODV (29%), conjugated ODV (26%), or other minor inactive metabolites (27%). Mean &plusmn; SD plasma steady-state clearances of venlafaxine and ODV are 1.3&plusmn;0.6 L/h/kg and 0.4&plusmn;0.2 L/h/kg, respectively.</p><p><u>Special populations</u></p><p><em>Age and gender</em></p><p>Subject age and gender do not significantly affect the pharmacokinetics of venlafaxine and ODV.</p><p><em>CYP2D6 extensive/poor metabolisers</em></p><p>Plasma concentrations of venlafaxine are higher in CYP2D6 poor metabolisers than extensive metabolisers. Because the total exposure (AUC) of venlafaxine and ODV is similar in poor and extensive metabolisers, there is no need for different venlafaxine dosing regimens for these two groups.</p><p><em>Hepatic impairment</em></p><p>In Child-Pugh A (mildly hepatically impaired) and Child-Pugh B (moderately hepatically impaired) subjects, venlafaxine and ODV half-lives were prolonged compared to normal subjects. The oral clearance of both venlafaxine and ODV was reduced. A large degree of intersubject variability was noted. There are limited data in patients with severe hepatic impairment (see section 4.2).</p><p><em>Renal impairment</em></p><p>In dialysis patients, venlafaxine elimination half-life was prolonged by about 180% and clearance reduced by about 57% compared to normal subjects, while ODV elimination half-life was prolonged by about 142% and clearance reduced by about 56%. Dosage adjustment is necessary in patients with severe renal impairment and in patients that require haemodialysis (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Studies with venlafaxine in rats and mice revealed no evidence of carcinogenesis. Venlafaxine was not mutagenic in a wide range of&nbsp;<em>in vitro</em>&nbsp;and&nbsp;<em>in vivo</em>&nbsp;tests.</p><p>Animal studies regarding reproductive toxicity have found in rats a decrease in pup weight, an increase in stillborn pups, and an increase in pup deaths during the first 5 days of lactation. The cause of these deaths is unknown. These effects occurred at 30 mg/kg/day, 4 times the human daily dose of 375 mg of venlafaxine (on an mg/kg basis). The no-effect dose for these findings was 1.3 times the human dose. The potential risk for humans is unknown.</p><p>Reduced fertility was observed in a study in which both male and female rats were exposed to ODV. This exposure was approximately 1 to 2 times that of a human venlafaxine dose of 375 mg/day. The human relevance of this finding is unknown.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Povidone (K30)</p><p>Isopropyl Alcohol</p><p>Calcium Hydrogen Phosphate (Di-Tab)</p><p>Magnesium Stearate.</p><p><em><u>Coating material:</u></em></p><p>Ethyl Cellulose (N50Pharm)</p><p>Hyperomellose</p><p>Isopropyl Alcohol</p><p>Methylene Chloride.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p><p>Store in the original pack to protect from light and moisture.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Venaxine<sup> </sup>XR 75 mg: Size &#39; 1 &#39; Capsules with peach coloured cap imprinted with &#39;RC22&#39; and peach coloured body, containing eight white to off white&nbsp; mini tablets, packed in Alu /PVC/PVDC- white blister, 14 Capsules/Blister, 1 Blister per box.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Keep medicines out of reach and sight of children</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O. Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing authorization holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2017 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>